Pancreatic Neuroendocrine Tumor Clinical Trial
Official title:
Endoscopic Ultrasound-guided Fine-needle Injection for Nonfunctional Pancreatic Neuroendocrine Tumors: a Prospective Multicenter Study
The current study aims to access the feasibility, safety, and efficacy of EUS-FNI for nonfunctional pNETs
The management of nonfunctional pancreatic neuroendocrine tumors (NF-pNETs) remains controversial. In general, surgical resection is the standard treatment for NF-pNETs. However, the incidence of postoperative adverse events of surgical resection is relatively high. Recently, several studies have revealed that endoscopic ultrasonography (EUS)-guided fine-needle injection (EUS-FNI) with ethanol or lauromacrogol may offer an effective treatment for pNETs. Therefore, a multicenter prospective study is being conducted to further identify the efficacy and safety of EUS-FNI for NF-pNETs. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00970970 -
Visualizing Vascular Endothelial Growth Factor (VEGF) Producing Lesions in Von Hippel-Lindau Disease
|
||
| Recruiting |
NCT05568017 -
Neoadjuvant PRRT With Y-90-DOTATOC in pNET
|
Phase 2 | |
| Not yet recruiting |
NCT06024343 -
Minimally Invasive Pancreatic Enucleation With Main Pancreatic Duct Repair or Reconstruction
|
N/A | |
| Recruiting |
NCT03891784 -
Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors
|
Phase 2 | |
| Recruiting |
NCT03204019 -
A Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Pancreatic Neuroendocrine Tumor
|
Phase 2 | |
| Completed |
NCT00804336 -
Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors
|
Phase 1 | |
| Recruiting |
NCT05997056 -
Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors
|
Phase 2 | |
| Not yet recruiting |
NCT06158516 -
A Study of Surufatinib as Adjuvant Therapy for Pancreatic Neuroendocrine Tumors
|
Phase 2 | |
| Recruiting |
NCT04119024 -
Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT05040360 -
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
|
Phase 2 | |
| Completed |
NCT00576680 -
RAD001 and Temozolomide in Patients With Advanced Pancreatic Neuroendocrine Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05610826 -
Preoperative PRRT Versus Surgical Cytoreduction in Metastatic Pancreatic Neuroendocrine Tumors to the Liver
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03074513 -
Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors
|
Phase 2 | |
| Completed |
NCT03967951 -
CT Radiomic Features of Pancreatic Neuroendocrine Neoplasms
|
||
| Completed |
NCT01024387 -
AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
|
Phase 2 | |
| Not yet recruiting |
NCT03435770 -
Evaluation of Safety and Feasibility of EUS-guided RFA for Solid Pancreatic Neoplasms
|
N/A | |
| Recruiting |
NCT04134832 -
Study of Pancreatic Neuroendocrine Tumors and Carcinomas in Alsace Region
|
||
| Recruiting |
NCT05554744 -
EUS-FNI for MEN1-related Pancreatic Neuroendocrine Tumors
|
N/A | |
| Completed |
NCT02159989 -
Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
|
Phase 1 | |
| Not yet recruiting |
NCT06406387 -
ATRX/DAXX in EUS-FNB Specimens of Pan-NETs
|